BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Bio company Alteogen secures major deal to export human hyaluronidase technology

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : December 2, 2019, 11:11 | Updated : December 2, 2019, 11:11
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Alteogen]

SEOUL -- Alteogen, a bio company in South Korea, has clinched a deal with an unspecified global pharmaceutical company to export its human hyaluronidase technology called ALT-B4 that can replace intravenous drugs with subcutaneous ones.

Alteogen said that ALT-B4 would be mixed with other biomedicine to develop and commercialize new products. The front payment is about 15.3 billion won ($12.9 million) and the contract's total value will be about 1.62 trillion won, including milestone payments which are paid when each milestone is achieved in clinical trials and commercialization.

Hyaluronidases, a family of enzymes that catalyze the degradation of hyaluronic acid, increase tissue permeability. They are used in medicine in conjunction with other drugs to speed their dispersion and delivery.

ALT-B4 uses a protein engineering technique called "Hybrozyme" and has improved biochemical properties while maintaining the inherent function of the previously known human hyaluronidase. KTB Investment & Securities said the deal with one of the world's 10 largest pharmaceutical companies demonstrated Alteogen's technical skills and raised the possibility of additional contracts.

"We are pleased to conclude a contract with a global pharmaceutical company for ALT-B4," said Alteogen CEO Park Soon-jae. "This contract has recognized the potential value of our technology." Park's company has patented a subcutaneous injectable formulation for ALT-LS2 that incorporates human hyaluronidase technology into its Herceptin biosimilar for breast cancer therapy. Herceptin has been developed by Genentech, a subsidiary of Swiss pharmaceutical giant Roche.

In June, Alteogen gained approval in South Korea to initiate a clinical trial for its aflibercept biosimilar, ALT‑L9, which is used to treat eye diseases, to evaluate the safety, efficacy and pharmacokinetics in patients with wet age-related macular degeneration.

Alteogen develops long-acting therapeutic proteins, therapeutic antibodies and monoclonal antibody biosimilars, with its portfolio including next-generation biobetters, an improved version of existing products, which may have a change in structure that makes it safer or more effective or a change in the formulation that makes it easier to administer or allows fewer courses of treatment.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Celltrion acquires European approval to sell Remsima SC for treatment of rheumatoid arthritis.
    Celltrion acquires European approval to sell Remsima SC for …
  • .Samsung Bioepis wins U.S. approval to sell biosimilar referencing Enbrel .
    Samsung Bioepis wins U.S. approval to sell biosimilar refere…
  • .Samsung BioLogics wins deal to produce CytoDyns drug candidate leronlimab.
    Samsung BioLogics wins deal to produce CytoDyn's drug candid…
  • .Biosimilar firm Celltrion plans to set up China joint venture in first half.
    Biosimilar firm Celltrion plans to set up China joint ventur…
  • .Celltrion wins recommendation to sell Remsima SC in Europe.
    Celltrion wins recommendation to sell Remsima SC in Europe

Real Time Photo News

  • .Singer Baek Yerin becomes first S. Korean artist to top song charts with English song.

    Singer Baek Yerin becomes first S. Korean artist to top song charts with English song

  • .[FOCUS] Transparency in compiling music charts becomes hot topic in music community.

    [FOCUS] Transparency in compiling music charts becomes hot topic in music community

  • .Actor Park Seo-joon expresses sadness over hacked YouTube channel.

    Actor Park Seo-joon expresses sadness over hacked YouTube channel

  • .Big Hit refutes JTBCs news report about BTS seeking legal help over profit distribution.

    Big Hit refutes JTBC's news report about BTS seeking legal help over profit distribution

  • .​[PHOTO] President Moon meets rock band U2s Bono.

    ​[PHOTO] President Moon meets rock band U2's Bono

Latest News

more+

  • Korean Air comes up with voluntary retirement program to reduce labor costs
  • Singer Baek Yerin becomes first S. Korean artist to top song charts with English song
  • [INTERVIEW] Neontech sees business growth in drone market dominated by Chinese products
  • ​Naver forges partnership with Woongjin Thinkbig to develop AI-based education platform
  • Guinness lists 5.08 km-long bar rice cake as new record holder
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view